Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8

Biotechnology and Bioengineering

Volumn 113, Issue 12, 2016, Pages 2712-2724

  Khabou, Hanen ^a   Desrosiers, Mélissa ^a   Winckler, Céline ^a   Fouquet, Stéphane ^a   Auregan, Gwenaëlle ^b,c   Bemelmans, Alexis Pierre ^b,c   Sahel, José Alain ^a,d   Dalkara, Deniz ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c CNRS   (France)

^d INSERM   (France)

Author keywords

AAV; directed evolution; gene delivery; gene therapy; retina

Indexed keywords

AMINO ACIDS; BACTERIOPHAGES; GENE THERAPY; GENE TRANSFER; GENES; OPHTHALMOLOGY; PEPTIDES; TISSUE; VIRUSES;

DEEP LAYER; DIRECTED EVOLUTION; GENE DELIVERY; MICROENVIRONMENTS; NEURAL TISSUE; RETINA; SEROTYPES; VIRAL PARTICLES;

GENE EXPRESSION;

7M8 PEPTIDE; AMINO ACID; ARGININE; GREEN FLUORESCENT PROTEIN; PEPTIDE; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG; CAPSID PROTEIN; RECOMBINANT PROTEIN;

ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE INSERTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MICROBIAL DIVERSITY; MOLECULAR MODEL; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; RECEPTOR BINDING; RETINA DEGENERATION; RETINAL TRANSDUCTION; SEROTYPE; STRUCTURAL MODEL; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS PARTICLE; VIRUS RECOMBINANT; ANIMAL; C57BL MOUSE; CHEMISTRY; CONFORMATION; DEPENDOPARVOVIRUS; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC VARIATION; GENETICS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; PROCEDURES; RETINA; ULTRASTRUCTURE; VIROLOGY;

ANIMALS; CAPSID PROTEINS; DEPENDOVIRUS; GENETIC VARIATION; GENETIC VECTORS; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR CONFORMATION; RECOMBINANT PROTEINS; RETINA; TRANSDUCTION, GENETIC;

EID: 84977517813     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.26031     Document Type: Article

References (58)

1. Afione S, DiMattia MA, Halder S, Di Pasquale G, Agbandje-McKenna M, Chiorini JA. 2015. Identification and mutagenesis of the adeno-associated virus 5 sialic acid binding region. J Virol 89:1660–1672.
2. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80:9831–9836.
3. Allocca M, Mussolino C, Garcia-Hoyos M, Sanges D, Iodice C, Petrillo M, Vandenberghe LH, Wilson JM, Marigo V, Surace EM, Auricchio A. 2007. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 81:11372–11380.
4. Arnett ALH, Beutler LR, Quintana A, Allen J, Finn E, Palmiter RD, Chamberlain JS. 2013. Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction. Gene Ther 20:497–503.
5. Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, Maguire AM, Wilson JM, Bennett J. 2001. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: The retina as a model. Hum Mole Genet 10:3075–3081.
6. Aurnhammer C, Haase M, Muether N, Hausl M, Rauschhuber C, Huber I, Nitschko H, Busch U, Sing A, Ehrhardt A, Baiker A. 2011. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther 23:18–28.
7. Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358:2231–2239.
8. Bainbridge JWB, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, Georgiadis A, Mowat FM, Beattie SG, Gardner PJ, Feathers KL, Luong VA, Yzer S, Balaggan K, Viswanathan A, de Ravel TJL, Casteels I, Holder GE, Tyler N, Fitzke FW, Weleber RG, Nardini M, Moore AT, Thompson DA, Petersen-Jones SM, Michaelides M, van den Born LI, Stockman A, Smith AJ, Rubin G, Ali RR. 2015. Long-term effect of gene therapy on leber's congenital amaurosis. N Engl J Med 372:1887–1897.
9. Bartlett JS, Wilcher R, Samulski RJ. 2000. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 74:2777–2785.
10. Bell CL, Gurda BL, Van Vliet K, Agbandje-McKenna M, Wilson JM. 2012. Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol 86:7326–7333.
11. Boyd RF, Sledge DG, Boye SL, Boye SE, Hauswirth WW, Komáromy AM, Petersen-Jones SM, Bartoe JT. 2015. Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs. Gene Ther 23:400.
12. Boye SL, Bennett A, Scalabrino ML, Mccullough KT, Van Vliet K, Choudhury S, Ruan Q, Peterson J, Agbandje-mckenna M, Boye E. 2016. Impact of heparan sulfate binding on transduction of retina by recombinant adeno-associated virus vectors. J Virol 90:4215–4231.
13. Byrne LC, Oztürk BE, Lee T, Fortuny C, Visel M, Dalkara D, Schaffer DV, Flannery JG. 2014. Retinoschisin gene therapy in photoreceptors, Müller glia or all retinal cells in the Rs1h-/- mouse. Gene Ther 21:585–592.
14. Byrne LC, Dalkara D, Luna G, Fisher SK, Clérin E, Sahel J, Léveillard T, Flannery JG. 2015. Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. J Clin Invest 125:105–116.
15. Cearley CN, Wolfe JH. 2006. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13:528–537.
16. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW. 2008. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 105(39):15112–15117.
17. Chivian D, Kim DE, Malmström L, Bradley P, Robertson T, Murphy P, Strauss CEM, Bonneau R, Rohl C a, Baker D. 2003. Automated prediction of CASP-5 structures using the robetta server. Proteins 53:524–533.
18. Choi VW, Asokan A, Haberman RA, Samulski RJ. 2007. Production of recombinant adeno-associated viral vectors. Curr Protoc Hum Genet 53:12.9:12.9.1–12.9.21.
19. Clark SJ, Keenan TDL, Fielder HL, Collinson LJ, Holley RJ, Merry CLR, van Kuppevelt TH, Day AJ, Bishop PN. 2011. Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera. Invest Opthalmol Vis Sci 52:6511.
20. Cronin T, Vandenberghe LH, Hantz P, Juttner J, Reimann A, Kacsó A-E, Huckfeldt RM, Busskamp V, Kohler H, Lagali PS, Roska B, Bennett J. 2014. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med 6:1–16.
21. Dalkara D, Byrne LLC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, Schaffer DV. 2013. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 5:189ra76.
22. Dalkara D, Kolstad KD, Caporale N, Visel M, Klimczak RR, Schaffer DV, Flannery JG. 2009. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 17:2096–2102.
23. DiMattia a M, Nam H-J, Van Vliet K, Mitchell M, Bennett a., Gurda BL, McKenna R, Olson NH, Sinkovits RS, Potter M, Byrne BJ, Aslanidi G, Zolotukhin S, Muzyczka N, Baker TS, Agbandje-McKenna M. 2012. Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol 86:6947–6958.
24. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, Kay MA. 2008. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 82:5887–5911.
25. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, Peden MC, Aleman TS, Boye SL, Sumaroka A, Conlon TJ, Calcedo R, Pang J, Erger KE. 2012. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: Safety and efficacy in fifteen children and adults followed up to three years. Arch Ophthalmol 130:9–24.
26. Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E, Hauswirth WW. 2015. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 372:1920–1926.
27. Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Sun J, Dyka FM, Kasuga D, Ayala AE, Van Vliet K, Agbandje-McKenna M, Hauswirth WW, Boye SL, Boye SE. 2013. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS ONE 8:e62097.
28. Kern A, Schmidt K, Leder C, Müller OJ, Wobus CE, Lieth CW, Von Der, King JA, Mu OJ, Bettinger K. 2003. Identification of a heparin-Binding motif on adeno-Associated virus type 2 capsids identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77:11072–11081.
29. Kim DE, Chivian D, Baker D. 2004. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 32:526–531.
30. Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM. 2006. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13:517–527.
31. Koerber JT, Jang J-H, Yu JH, Kane RS, Schaffer DV. 2007. Engineering adeno-associated virus for one-step purification via immobilized maffinity chromatography. Hum Gene Ther 18:367–378.
32. Lochrie M a, Tatsuno GP, Christie B, Mcdonnell JW, Zhou S, Pierce GF, Colosi P, Surosky R. 2006. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 80:821–834.
33. Macé E, Caplette R, Marre O, Sengupta A, Chaffiol A, Barbe P, Desrosiers M, Bamberg E, Sahel J-A, Picaud S, Duebel J, Dalkara D. 2014. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. Mol Ther 23:7–16.
34. MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L, Clark KR, During MJ, Cremers FPM, Black GCM, Lotery AJ, Downes SM, Webster AR, Seabra MC. 2014. Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1/2 clinical trial. Lancet 383:1129–1137.
35. Maguire AM, Simonelli F, Pierce EA, Pugh EN, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma J, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. 2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. New Engl J Med 358:2240–2248.
36. Michelfelder S, Varadi K, Raupp C, Hunger A, Körbelin J, Pahrmann C, Schrepfer S, Müller OJ, Kleinschmidt a J, Trepel M. 2011. Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6:e23101.
37. Mowat FM, Gornik KR, Dinculescu A, Boye SL, Hauswirth WW, Petersen-Jones SM, Bartoe JT. 2014. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene Ther 21:96–105.
38. Nam H-J, Lane MD, Padron E, Gurda B, McKenna R, Kohlbrenner E, Aslanidi G, Byrne B, Muzyczka N, Zolotukhin S, Agbandje-McKenna M. 2007. Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol 81:12260–12271.
39. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, Nawathe S, Waddington SN, Bronson R, Jackson S, Donahue RE, High KA, Mingozzi F, Ng CYC, Zhou J, Spence Y, McCarville MB, Valentine M, Allay J, Coleman J, Sleep S, Gray JT, Nienhuis AW, Davidoff AM. 2011. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 19:876–885.
40. Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen Y-M, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CYC, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. 2014. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371:1994–2004.
41. Natkunarajah M, Trittibach P, McIntosh J, Duran Y, Barker SE, Smith a J, Nathwani a C, Ali RR. 2008. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther 15:463–467.
42. Nguyen JB, Sanchez-Pernaute R, Cunningham J, Bankiewicz KS. 2001. Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 12:1961–1964.
43. Opie SR, Warrington KH, Agbandje-McKenna M, Zolotukhin S, Muzyczka N. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77:6995–7006.
44. Perabo L, Goldnau D, White K, Endell J, Boucas J, Humme S, Work LM, Janicki H, Hallek M, Baker AH, Büning H. 2006. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 80:7265–7269.
45. Petrs-silva H, Dinculescu A, Li Q, Deng W, Pang J, Min S, Chiodo V, Neeley AW, Govindasamy L, Bennett A, Agbandje-McKenna M, Zhong L, Li B, Jayandharan GR, Srivastava A, Lewin AS, Hauswirth WW. 2011. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 19:293–301.
46. Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J, Zhong L, Zolotukhin S, Srivastava A, Lewin AS, Hauswirth WW. 2009. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 17:463–471.
47. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF chimera—A visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612.
48. Raupp C, Naumer M, Muller OJ, Gurda BL, Agbandje-McKenna M, Kleinschmidt J a. 2012. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol 86:9396–9408.
49. Schmidt M, Govindasamy L, Afione S, Kaludov N, Agbandje-McKenna M, Chiorini JA. 2008. Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J Virol 82:8911–8916.
50. Shen S, Berry GE, Castellanos Rivera RM, Cheung RY, Troupes AN, Brown SM, Kafri T, Asokan A. 2014. Functional analysis of the putative integrin recognition motif on adeno-associated virus 9. J Biolo Chem 290:1496–1504.
51. Vandenberghe LH, Auricchio A. 2012. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther 19:162–168.
52. Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R, Wang L, Castle MJ, Maguire AC, Grant R, Wolfe JH, Wilson JM, Bennett J. 2011. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 3:88ra54.
53. Vandenberghe LH, Bell P, Maguire AM, Xiao R, Hopkins TB, Grant R, Bennett J, Wilson JM. 2013. AAV9 targets cone photoreceptors in the nonhuman primate retina. PLoS ONE 8:e53463.
54. Varadi K, Michelfelder S, Korff T, Hecker M, Trepel M, Katus a H, Kleinschmidt a J, Müller OJ. 2012. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther 19:800–809.
55. Walters RW, Agbandje-mckenna M, Valorie D, Moninger TO, Olson NH, Chiorini JA, Baker TS, Bowman VD, Seiler M, Zabner J. 2004. Structure of adeno-associated virus structure of adeno-associated virus serotype 5. J Virol 78:3361–3371.
56. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74:8635–8647.
57. Ying Y, Müller OJ, Goehringer C, Leuchs B, Trepel M, Katus a H, Kleinschmidt a J. 2010. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 17:980–990.
58. Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R, Xu Z, Gao G. 2011. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19:1440–1448.